Tag Archives: British

Rejected Drug

UK Cost Agency Rejects British Company GW’s Cannabis Drug

UK Cost Agency Rejects British Company GW’s Cannabis Drug

LONDON, Oct 8 (Reuters) – A pioneering cannabis drug developed by British firm GW Pharmaceuticals for treating spasticity in multiple sclerosis has been rejected as not cost-effective in the company’s home market.


Top